GlassScriptPhysician profile
Sheena Urdaz
NPI 1083020408
$4,680.61
in general payments reported to CMS, 2019-2025
23 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,029 · 2022: $467 · 2023: $738 · 2024: $1,423 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,177.98 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.03 | 2021-2024 | Jardiance |
| Abbott Laboratories | $550.57 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $339.18 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $309.21 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $231.40 | 2023-2025 | |
| Pfizer INC. | $221.32 | 2021-2025 | |
| Esperion Therapeutics, INC. | $221.06 | 2021-2025 | Nexletol |
| Glaxosmithkline, LLC. | $174.13 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $148.18 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $140.49 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $133.41 | 2025 | |
| Currax Pharmaceuticals LLC | $93.36 | 2021-2022 | |
| Organon LLC | $69.72 | 2022 | |
| Abbvie INC. | $38.56 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.86 | 2024 | |
| Viatris Specialty LLC | $30.72 | 2025 | Yupelri |
| Dexcom, INC. | $24.05 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $21.60 | 2022 | |
| Hologic Sales and Service, LLC | $19.88 | 2023 | Thinprep 2000 Processor, Aptima |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.23 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $17.91 | 2024 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $13.76 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Urdaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.